<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="32366663201919287 doi: 10.1073/pnas.1919287117 : Biological Sciences: Microbiology Positive epistasis between" exact="viral" post="polymerase and the 3′ untranslated region of its genome"/>
 <result pre="distributed under Creative Commons Attribution License 4.0 (CC BY).pnas.201919287.pdf Significance" exact="Dengue" post="affects approximately one-half of the world’s population. While it"/>
 <result pre="to intercept impending outbreaks before many lives are affected. Abstract" exact="Dengue" post="virus (DENV) is a global health threat, causing repeated"/>
 <result pre="the four antigenic types of DENV predispose populations to outbreaks," exact="viral" post="genetic determinants that confer greater fitness for epidemic spread"/>
 <result pre="positive epistasis between the coding and noncoding regions of the" exact="viral" post="genome combined to elicit an epidemiologic fitness phenotype associated"/>
 <result pre="that five amino acid substitutions in the NS5 protein reduced" exact="viral" post="genomic RNA (gRNA) replication rate to achieve a more"/>
 <result pre="increase in sfRNA relative to gRNA levels not only inhibited" exact="type I" post="interferon (IFN) expression in infected cells through a previously"/>
 <result pre="also enabled sfRNA to compete with gRNA for packaging into" exact="infectious" post="particles. We suggest that delivery of sfRNA to new"/>
 <result pre="that delivery of sfRNA to new susceptible cells to inhibit" exact="type I" post="IFN induction before gRNA replication and without the need"/>
 <result pre="TanMilly M. ChoyTanamas SiriphanitchakornColin ChengSubhash G VasudevanEng Eong Ooi page-count:" exact="Dengue" post="is the most common vector-borne viral disease globally. Dengue"/>
 <result pre="VasudevanEng Eong Ooi page-count: Dengue is the most common vector-borne" exact="viral" post="disease globally. Dengue virus (DENV), which exists as four"/>
 <result pre="Eong Ooi page-count: Dengue is the most common vector-borne viral" exact="disease" post="globally. Dengue virus (DENV), which exists as four antigenically"/>
 <result pre="page-count: Dengue is the most common vector-borne viral disease globally." exact="Dengue" post="virus (DENV), which exists as four antigenically distinct serotypes,"/>
 <result pre="serotypes, afflicts an estimated 100 million people each year with" exact="acute" post="disease, some of which are life-threatening (1). The geographic"/>
 <result pre="trade and travel (2). Without a vaccine that effectively prevents" exact="infection" post="by all four DENV serotypes or a licensed drug"/>
 <result pre="serotypes or a licensed drug that can rapidly knock down" exact="viral" post="burden in dengue patients and thereby reduce the likelihood"/>
 <result pre="likelihood of DENV transmission, cyclical dengue epidemics will continue to" exact="plague" post="global health. Dengue epidemics are mostly thought to result"/>
 <result pre="transmission, cyclical dengue epidemics will continue to plague global health." exact="Dengue" post="epidemics are mostly thought to result from the emergence"/>
 <result pre="emerged and displaced endemic strains without a change in either" exact="viral" post="serotype or genotype. Such instances have been observed in"/>
 <result pre="also could be developed into DENV genomic surveillance that scales" exact="disease" post="prevention measures based on genetically defined risk of outbreaks"/>
 <result pre="three mutations in the 3′ untranslated region (UTR) of the" exact="viral" post="genome (12). These mutations led to production of more"/>
 <result pre="production of more subgenomic flavivirus RNA (sfRNA) relative to genomic" exact="viral" post="RNA (gRNA) in PR2B viruses (12). The formation of"/>
 <result pre="3′ direction but stalls when the enzyme encounters highly conserved" exact="secondary" post="RNA structures in the 3′ UTR (13); thus, sfRNAs"/>
 <result pre="activity on RIG-I, which is necessary for sustained and amplified" exact="type I" post="IFN induction. Thus, a reduced IFN response could have"/>
 <result pre="viremia titers during human infection, increasing the likelihood of a" exact="symptomatic" post="outcome as well as transmission to blood-feeding Aedes mosquito"/>
 <result pre="that led to the 1994 dengue outbreak, we reconstructed the" exact="viral" post="ancestors and estimated the time in which the genetic"/>
 <result pre="variants emerged. We found that the 3′ UTR mutations were" exact="acquired" post="as early as 1985, 9 y before the outbreak."/>
 <result pre="found mostly in the nonstructural 5 (NS5) gene, which encodes" exact="viral" post="methyltransferase and RNA-dependent RNA polymerase (RdRP). We show here"/>
 <result pre="sfRNA to be packaged into DENV envelope (E) protein containing" exact="infectious" post="particles. Thus, on infection, sfRNA could be delivered to"/>
 <result pre="immune evasive function of sfRNA. Results PR2B NS5 Substitutions Were" exact="Acquired" post="Immediately before the 1994 Outbreak. To systemically define the"/>
 <result pre="from an online database, the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) Virus Pathogen Database and Analysis Resource (ViPR)"/>
 <result pre="an online database, the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) Virus Pathogen Database and Analysis Resource (ViPR) (18)."/>
 <result pre="Pathogen Database and Analysis Resource (ViPR) (18). Mapping the mutations" exact="acquired" post="by PR2B on to the branches of the tree"/>
 <result pre="Fig. S1). We next ascertained when these NS5 mutations were" exact="acquired" post="relative to the three nucleotide mutations in the 3′"/>
 <result pre="effect that NS5 mutations had on PR2B infection, we generated" exact="infectious" post="clone of PR2B and used reverse genetics to rescue"/>
 <result pre="intermediates onto human hepatoma (Huh-7) cells at a multiplicity of" exact="infection" post="(MOI) of 0.1 produced gRNA levels (Fig. 1B) and"/>
 <result pre="infection (MOI) of 0.1 produced gRNA levels (Fig. 1B) and" exact="infectious" post="viral progenies (Fig. 1C) that were intermediate to those"/>
 <result pre="(MOI) of 0.1 produced gRNA levels (Fig. 1B) and infectious" exact="viral" post="progenies (Fig. 1C) that were intermediate to those of"/>
 <result pre="(Fig. 1B) and infectious viral progenies (Fig. 1C) that were" exact="intermediate" post="to those of the control PR1 and PR2B viruses"/>
 <result pre="1E). Correspondingly, IFN-β expression was increased (Fig. 1F). Table 1." exact="Infectious" post="clones generated on PR1 and PR2B backbones bearing NS5"/>
 <result pre="A G T To confirm the foregoing findings, we generated" exact="infectious" post="clones with a PR1 genomic backbone and replaced its"/>
 <result pre="(PR1NS5) PR2B 3′ UTR, resulted in reduced gRNA levels in" exact="primary" post="monocytes (Fig. 2A). In contrast, replacement of PR1 3′"/>
 <result pre="PR13UTR-infected cells (Fig. 2C). IFN-β expression was likewise reduced in" exact="primary" post="monocytes infected with PR1NS53UTR and PR2B DENV2, but not"/>
 <result pre="sfRNA:gRNA ratios (C), and mRNA expression of IFN-β (D) in" exact="primary" post="monocytes by RT-qPCR. (E) Quantification of gRNA levels in"/>
 <result pre="0.0001, unpaired t test. ns, not significant. Our findings in" exact="primary" post="monocytes were reproduced in two different cell lines, the"/>
 <result pre="monocytes were reproduced in two different cell lines, the lung" exact="epithelial" post="A549 (SI Appendix, Fig. S2 A–D) and Huh7 (SI"/>
 <result pre="Northern blot analysis (SI Appendix, Fig. S2I). Furthermore, assessment of" exact="viral" post="kinetics of all our mutant viruses in A549 cells"/>
 <result pre="and increasing sfRNA relative to gRNA levels. We generated five" exact="infectious" post="clones of PR1, each bearing one of the five"/>
 <result pre="2E) and pfu (Fig. 2F). Likewise, sfRNA levels were universally" exact="lower" post="for all mutants (Fig. 2G). The sfRNA:gRNA ratio (Fig."/>
 <result pre="could have resulted in reduced PR2B gRNA binding and thus" exact="viral" post="replication (Fig. 2 E and F), which is consistent"/>
 <result pre="PR2B compared with PR1 NS5 protein (SI Appendix, Fig. S2M)." exact="Reduced" post="gRNA Replication Is Required for Augmenting sfRNA:gRNA Ratios. Reduced"/>
 <result pre="S2M). Reduced gRNA Replication Is Required for Augmenting sfRNA:gRNA Ratios." exact="Reduced" post="gRNA levels in PR2B compared with PR1 may be"/>
 <result pre="substrate would result in an excess enzyme-to-substrate ratio for more" exact="complete" post="digestion of uncapped gRNA to form sfRNA. If this"/>
 <result pre="inhibit DENV polymerase activity (22). Indeed, cotreatment of NITD008 yielded" exact="lower" post="gRNA levels at 24 hpi for both PR1 and"/>
 <result pre="for more favorable sfRNA production relative to gRNA. Fig. 3." exact="Reduced" post="gRNA replication is required for an increased sfRNA:gRNA ratio."/>
 <result pre="ANOVA. High sfRNA:gRNA Ratios Enable Encapsidation of sfRNA in Envelope-Containing" exact="Infectious" post="Particles. We had previously suggested that a higher sfRNA-to-gRNA"/>
 <result pre="RIG-I signaling before gRNA replication ensues. Packaging of sfRNA into" exact="infectious" post="particles is plausible, as a recent study showed that"/>
 <result pre="the culture supernatant of infected A549 cells (Fig. 4A) and" exact="primary" post="monocytes (SI Appendix, Fig. S4F). We validated this result"/>
 <result pre="the sfRNA band, which could be indicative of defective interfering" exact="viral" post="particles, as described previously (25). Fig. 4. PR2B sfRNA"/>
 <result pre="(25). Fig. 4. PR2B sfRNA is packaged inside E protein-containing" exact="infectious" post="particles and transmitted into new susceptible cells. (A) Quantification"/>
 <result pre="PR1, and PR1NS53UTR and cotreatment of NITD008. (K) Level of" exact="infection" post="with MOIs of 1 and 10 of mock, PR1,"/>
 <result pre="are secreted from cells via exocytosis, which could contain both" exact="viral" post="RNA and virions (26–28). Thus, we measured the levels"/>
 <result pre="CD9, CD63, CD81, and CD151 in A549 cells resulted in" exact="lower" post="gRNA copies (SI Appendix, Fig. S4 G and I)"/>
 <result pre="exosomes. To determine whether sfRNA is packaged in virions or" exact="infectious" post="particles containing DENV envelope (E) protein and are thus"/>
 <result pre="used a pan-DENV monoclonal antibody, 4G2, to enrich for E-containing" exact="infectious" post="particles in the culture supernatant. An overview of the"/>
 <result pre="to RNase treatment (SI Appendix, Fig. S5C) to remove unpackaged" exact="viral" post="RNA before viral envelope was digested for viral RNA"/>
 <result pre="(SI Appendix, Fig. S5C) to remove unpackaged viral RNA before" exact="viral" post="envelope was digested for viral RNA extraction. RT-qPCR showed"/>
 <result pre="remove unpackaged viral RNA before viral envelope was digested for" exact="viral" post="RNA extraction. RT-qPCR showed that gRNA copies were detectable"/>
 <result pre="4E). These findings suggest that sfRNA could be packaged in" exact="infectious" post="particles. However, the 4G2 pull-down precipitate also contained exosomes"/>
 <result pre="our experiment, we also silenced XRN1 in the inoculated cells." exact="Reduced" post="XRN1 expression did not affect the levels of either"/>
 <result pre="we tested whether the packaged sfRNA can indeed inhibit the" exact="type I" post="IFN response directly on delivery to new susceptible cells."/>
 <result pre="at a concentration of 27 μM to ensure inhibition of" exact="viral" post="replication and de novo synthesis of sfRNA. We then"/>
 <result pre="then assessed the levels of phosphorylated IRF3 at 6 hpi." exact="Infection" post="at an MOI of 1 resulted in few to"/>
 <result pre="compared with PR1 (Fig. 4J), indicating early inhibition of the" exact="type I" post="IFN response. Taken together, our data hint at the"/>
 <result pre="possibility that sfRNA can be packaged in DENV E protein-containing" exact="infectious" post="particles and delivered into cells for direct inhibition of"/>
 <result pre="particles and delivered into cells for direct inhibition of the" exact="type I" post="IFN response but in a DENV strain-dependent manner. Discussion"/>
 <result pre="enabled it to compete favorably with gRNA for packaging into" exact="infectious" post="particles. Our Bayesian molecular dating analysis revealed that PR2B"/>
 <result pre="molecular dating analysis revealed that PR2B 3′ UTR mutations were" exact="acquired" post="well before the 1994 outbreak. Mutations in the coding"/>
 <result pre="the coding region (NS1, NS3, and NS5) of PR2B were" exact="acquired" post="after those in the 3′ UTR. These mutations also"/>
 <result pre="(31), which has been shown to be a mediator of" exact="vascular" post="leakage (32). Consequently, this T164S mutation also could have"/>
 <result pre="Consequently, this T164S mutation also could have contributed to more" exact="severe dengue" post="and hence more healthcare-seeking patients. However, of the eight"/>
 <result pre="stem-loop A for initiation of de novo synthesis of the" exact="viral" post="genome (37–39). Introduction of PR2B NS5 mutations into the"/>
 <result pre="NS5 mutations into the PR1 genomic backbone produced mutants with" exact="lower" post="rates of gRNA replication. Since an arginine patch in"/>
 <result pre="patch in the RdRp may play a role in facilitating" exact="viral" post="RNA binding (20), the R-to-K substitutions (R596K, R514K, and"/>
 <result pre="binding to the polymerase, thereby reducing the gRNA replication rate." exact="Reduced" post="gRNA could be important to ensure that XRN1 levels"/>
 <result pre="We now show that that sfRNA could be delivered in" exact="infectious" post="particles and serve as a form of &quot;preemptive strike.�?"/>
 <result pre="as a form of &quot;preemptive strike.�? Delivery of sfRNA in" exact="infectious" post="particles would inhibit RIG-I before de novo gRNA replication,"/>
 <result pre="stimulate RIG-I. Histologically, DENV replication and encapsidation occur concurrently in" exact="vesicle" post="packets (VPs) on membranes of the endoplasmic reticulum (ER)"/>
 <result pre="membranes of the endoplasmic reticulum (ER) (40). Synthesized negatively charged" exact="viral" post="RNA exits through VP pores and is transported into"/>
 <result pre="285 nucleotides of the 3′ UTR facilitates transport of the" exact="viral" post="RNA to the virion assembly site (23). As sfRNA"/>
 <result pre="As sfRNA formation follows gRNA replication and thus is also" exact="localized" post="within the reorganized ER, excess sfRNA could conceivably compete"/>
 <result pre="conceivably compete with gRNA for packaging or even encapsidation into" exact="infectious" post="particles or virions. To our knowledge, this finding has"/>
 <result pre="formed and characterizes its multifaceted role in immune evasion through" exact="viral" post="RNA–host protein interactions (12, 14, 41–43). Our results also"/>
 <result pre="41–43). Our results also show that packaging of sfRNA into" exact="infectious" post="particles is dependent on the strain of DENV, as"/>
 <result pre="dengue outbreak in 1994. Mutations in the 3 ′UTR were" exact="acquired" post="possibly as early as 1985, although the type I"/>
 <result pre="′UTR were acquired possibly as early as 1985, although the" exact="type I" post="IFN repression phenotype could not be revealed until the"/>
 <result pre="not be revealed until the mutations in the NS5 were" exact="acquired" post="just before the 1994 outbreak. We speculate that if"/>
 <result pre="rate of gRNA replication without the ability to effectively suppress" exact="type I" post="IFN expression likely would have resulted in a DENV"/>
 <result pre="cultured in RPMI 1640 (Gibco) with 10% FBS. Isolation of" exact="Primary" post="Monocytes. Peripheral blood mononuclear cell (PBMC)-derived primary monocytes were"/>
 <result pre="FBS. Isolation of Primary Monocytes. Peripheral blood mononuclear cell (PBMC)-derived" exact="primary" post="monocytes were isolated from flavivirus-naïve healthy donors according to"/>
 <result pre="were deidentified before use in experiments. Synthesis and Mutagenesis of" exact="Infectious" post="Clones. DENV2 infectious clones were constructed using the Gibson"/>
 <result pre="use in experiments. Synthesis and Mutagenesis of Infectious Clones. DENV2" exact="infectious" post="clones were constructed using the Gibson assembly method (45,"/>
 <result pre="constructed using the Gibson assembly method (45, 46). In brief," exact="viral" post="RNA was extracted from strain PR1940 (representing the Puerto"/>
 <result pre="(representing the Puerto Rico epidemic clade PR2B) using the QIAamp" exact="Viral" post="RNA Mini Kit (Qiagen) according to the manufacturer’s instructions."/>
 <result pre="used to synthesize six DNA fragments that amount to the" exact="complete" post="DENV genome using Q5 Hotstart 2× Master Mix (New"/>
 <result pre="used for transfection, and supernatant was collected 48 h later." exact="Infectious" post="clones were propagated in C6/36 cells supplemented with 3%"/>
 <result pre="d), harvested, and stored at −80 °C until further use." exact="Viral" post="titers were determined by plaque assay. Infectious clones used"/>
 <result pre="until further use. Viral titers were determined by plaque assay." exact="Infectious" post="clones used in subsequent experiments were passaged one to"/>
 <result pre="were passaged one to three times in C6/36 cells. Synthesized" exact="infectious" post="clones were confirmed by Sanger sequencing as described previously"/>
 <result pre="(49). After alignment, the dataset was scanned to identify any" exact="incomplete" post="sequences or sequencing errors that may have resulted in"/>
 <result pre="1.4.2. Virus Quantification. A plaque assay was performed to quantify" exact="viral" post="titers as described previously (44) using maintenance RPMI 1640"/>
 <result pre="described previously (44) using maintenance RPMI 1640 on BHK21 cells." exact="Viral" post="titers were calculated as pfu/μL. Virus Infection. Assessment of"/>
 <result pre="supernatant were done using the RNeasy Mini Kit and QIAamp" exact="Viral" post="RNA Mini Kit, respectively (Qiagen) according to the manufacturer’s"/>
 <result pre="was performed using the qScript cDNA Synthesis Kit (Quantas Biosciences)." exact="Viral" post="replication kinetics were measured by RT-qPCR using the SYBR"/>
 <result pre="analysis was performed with LightCycler 480 software. The amount of" exact="viral" post="RNA present in cell lysates was calculated as the"/>
 <result pre="described above. Cell lysate was harvested at 24 hpi for" exact="viral" post="RNA extraction using TRIzol (Life Technologies). Samples were run"/>
 <result pre="twice with PBS and then being stored at 4 °C." exact="Nonspecific" post="binding was blocked by 30 min of incubation with"/>
 <result pre="incubation with 1% [wt/vol] BSA/PBS before incubation of cells with" exact="primary" post="antibodies against NS5 (5R3, 30 nM), followed by incubation"/>
 <result pre="antibodies against NS5 (5R3, 30 nM), followed by incubation with" exact="secondary" post="antibodies coupled to Alexa Fluor 488 or Alexa Fluor"/>
 <result pre="PBS containing either 5% nonfat dry milk or 5% BSA." exact="Primary" post="antibodies were diluted in blocking buffer. The denaturing condition"/>
 <result pre="for CD9 (Abcam; 1:500), CD81 (Abcam; 1:250), and CD151 (Thermo" exact="Fisher" post="Scientific; 1:1,000). Secondary antibodies (anti-rabbit, 1:5,000, and anti-mouse, 1:5,000)"/>
 <result pre="1:500), CD81 (Abcam; 1:250), and CD151 (Thermo Fisher Scientific; 1:1,000)." exact="Secondary" post="antibodies (anti-rabbit, 1:5,000, and anti-mouse, 1:5,000) were diluted in"/>
 <result pre="h. Knockdown efficiencies were evaluated by Western blot analysis. NITD008" exact="Infection" post="Assay. A549 cells were infected with virus at an"/>
 <result pre="lysates were harvested 24 at hpi for RT-qPCR quantification of" exact="viral" post="gRNA and sfRNA as described above. Virus Pull-Down Assay."/>
 <result pre="described above. Virus Pull-Down Assay. A549 cells were infected with" exact="infectious" post="clones at an MOI of 1 and incubated for"/>
 <result pre="4G2. The pull-down fraction was subsequently treated with RNAse, and" exact="viral" post="RNA extraction was performed using the Qiagen QIAamp Viral"/>
 <result pre="and viral RNA extraction was performed using the Qiagen QIAamp" exact="Viral" post="RNA Mini Kit. Following RNA extraction, cDNA synthesis and"/>
 <result pre="FileLINK We thank Katell Bidet for providing the vector for" exact="infectious" post="clones and Yeh Shih-Chia for help with the Northern"/>
 <result pre="at risk of dengue. Nat. Microbiol.4, 1508–1515 (2019).31182801 3GublerD. J.," exact="Epidemic" post="dengue/dengue hemorrhagic fever as a public health, social and"/>
 <result pre="dengue 2 virus in Puerto Rico: Positive selection in the" exact="viral" post="envelope accompanies clade reintroduction. J. Gen. Virol.87, 885–893 (2006).16528038"/>
 <result pre="accompanies clade reintroduction. J. Gen. Virol.87, 885–893 (2006).16528038 6LeeK.-S.et al.," exact="Dengue" post="virus surveillance for early warning, Singapore. Emerg. Infect. Dis.16,"/>
 <result pre="PLoS Negl. Trop. Dis.4, e757 (2010).20651932 8OhAinleM.et al., Dynamics of" exact="dengue disease" post="severity determined by the interplay between viral genetics and"/>
 <result pre="Negl. Trop. Dis.4, e757 (2010).20651932 8OhAinleM.et al., Dynamics of dengue" exact="disease" post="severity determined by the interplay between viral genetics and"/>
 <result pre="Dynamics of dengue disease severity determined by the interplay between" exact="viral" post="genetics and serotype-specific immunity. Sci. Transl. Med.3, 114ra128 (2011)."/>
 <result pre="al., Inter- and intra-host sequence diversity reveal the emergence of" exact="viral" post="variants during an overwintering epidemic caused by dengue virus"/>
 <result pre="Taiwan. PLoS Negl. Trop. Dis.12, e0006827 (2018).30286095 10PinheiroT. M.et al.," exact="Viral" post="immunogenicity determines epidemiological fitness in a cohort of DENV-1"/>
 <result pre="Viral immunogenicity determines epidemiological fitness in a cohort of DENV-1" exact="infection" post="in Brazil. PLoS Negl. Trop. Dis.12, e0006525 (2018).29813061 11.OoiE.-E.,"/>
 <result pre="on Dengue, (World Health Organization, 2007), pp. 124–133. 12ManokaranG.et al.," exact="Dengue" post="subgenomic RNA binds TRIM25 to inhibit interferon expression for"/>
 <result pre="subcellular localization and contains a conserved arginine residue essential for" exact="infectious" post="virus production. PLoS Pathog.12, e1005886 (2016).27622521 22YinZ.et al., An"/>
 <result pre="virus. Proc. Natl. Acad. Sci. U.S.A.106, 20435–20439 (2009).19918064 23XieX.et al.," exact="Dengue" post="NS2A protein orchestrates virus assembly. Cell Host Microbe26, 606–622.e8"/>
 <result pre="NS2A-mediated virion assembly. mBio10, e02375-19 (2019).31662457 25LiD.et al., Defective interfering" exact="viral" post="particles in acute dengue infections. PLoS One6, e19447 (2011).21559384"/>
 <result pre="mBio10, e02375-19 (2019).31662457 25LiD.et al., Defective interfering viral particles in" exact="acute" post="dengue infections. PLoS One6, e19447 (2011).21559384 26NourA. M., ModisY.,"/>
 <result pre="e19447 (2011).21559384 26NourA. M., ModisY., Endosomal vesicles as vehicles for" exact="viral" post="genomes. Trends Cell Biol.24, 449–454 (2014).24746011 27VoraA.et al., Arthropod"/>
 <result pre="AlvesL. R., Characterization of dendritic cell-derived extracellular vesicles during dengue" exact="virus infection." post="Front. Microbiol.9, 1792 (2018).30131785 29ChanK. R.et al., Leukocyte immunoglobulin-like"/>
 <result pre="dengue virus infection. Front. Microbiol.9, 1792 (2018).30131785 29ChanK. R.et al.," exact="Leukocyte" post="immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc."/>
 <result pre="(2014).24550301 30KooC.et al., Highly selective transmission success of dengue virus" exact="type 1" post="lineages in a dynamic virus population: An evolutionary and"/>
 <result pre="in the dengue virus NS1 protein is associated with greater" exact="disease" post="severity in mice. Sci. Transl. Med.11, eaat7726 (2019).31243154 32BeattyP."/>
 <result pre="in mice. Sci. Transl. Med.11, eaat7726 (2019).31243154 32BeattyP. R.et al.," exact="Dengue" post="virus NS1 triggers endothelial permeability and vascular leak that"/>
 <result pre="32BeattyP. R.et al., Dengue virus NS1 triggers endothelial permeability and" exact="vascular" post="leak that is prevented by NS1 vaccination. Sci. Transl."/>
 <result pre="Sci. Transl. Med.7, 304ra141 (2015). 33ChoiK. H., &quot;Viral polymerases�? in" exact="Viral" post="Molecular Machines, RossmannM. G., RaoV. B., Eds. (Springer, 2012),"/>
 <result pre="Virol.81, 4753–4765 (2007).17301146 35KroschewskiH.et al., Mutagenesis of the dengue virus" exact="type 2" post="NS5 methyltransferase domain. J. Biol. Chem.283, 19410–19421 (2008).18469001 36TeramotoT.,"/>
 <result pre="2 nonstructural proteins (NS) 5 and NS3 are crucial for" exact="viral" post="RNA replication. J. Biol. Chem.292, 9465–9479 (2017).28396347 37BujalowskiP. J.,"/>
 <result pre="of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue" exact="virus infection." post="Proc. Natl. Acad. Sci. U.S.A.108, 12479–12484 (2011).21746897 45GibsonD. G.et"/>
</results>
